Latest Content

Chimeric antigen receptor T-cell therapies, along with bispecific antibodies, have changed the treatment paradigm for patients with relapsed or refractory mantle cell lymphoma.

A new analysis based on two prospective trials helps clarify the roles of chemotherapy and radiotherapy.

Chronic kidney disease now affects more than 788 million adults globally, with rising prevalence, increasing mortality, and substantial contributions to cardiovascular deaths

A study identified 32 dysregulated cytokines and 5 key signaling hubs in idiopathic pulmonary fibrosis (IPF), mapping a complex network of profibrotic pathways that may serve as future therapeutic targets.

A combined assessment of genetic, serologic, and clinical factors may enhance early recognition of patients with RA who are most at risk for ILD.

Modern ibrutinib-based approaches substantially narrow the traditional survival gap observed in CLL.

Most US patients eligible for hepatitis B virus (HBV) treatment remain untreated, raising risks of liver disease and complications.

Baricitinib demonstrated significant reductions in disease activity in postmenopausal women with frontal fibrosing alopecia over 12 weeks.

The FDA expanded approvals for key medications, enhancing treatment options for atopic dermatitis, inflammatory bowel disease, type 2 diabetes, and more.